138 results about "Seroma" patented technology

A flexible medical closure screen device for a separation of first and second tissue portions is provided, which includes a mesh screen comprising tubular vertical risers, vertical strands with barbed filaments, and horizontal spacers connecting the risers and strands in a grid-like configuration. An optional perimeter member partly surrounds the screen and can comprise a perimeter tube fluidically coupled with the vertical risers to form a tubing assembly. Various input/output devices can optionally be connected to the perimeter tube ends for irrigating and/or draining the separation according to methodologies of the present invention. Separation closure, irrigation and drainage methodologies are disclosed utilizing various combinations of closure screens, tubing, sutures, fluid transfer elements and gradient force sources. The use of mechanical forces associated with barbed strands for repositionably securing separated tissues together is disclosed. The use of same for eliminating or reducing the formation of subcutaneous voids or pockets, which can potentially form hematoma and seroma effects, is also disclosed. Alternative embodiments of the invention have circumferential configurations for approximating and closing separated tissue portions such as tendons, nerves and blood vessels. Tissue closure methods include the steps of circumferentially applying a screen to separated tissue portions and penetrating the tissue portions with prongs.

A medical closure screen device for a separation of first and second tissue portions is provided, which includes a mesh screen comprising tubular vertical risers, vertical strands with barbed filaments, and horizontal spacers connecting the risers and strands in a grid-like configuration. An optional perimeter member partly surrounds the screen and can comprise a perimeter tube fluidically coupled with the vertical risers to form a tubing assembly. Various input/output devices can optionally be connected to the perimeter tube ends for irrigating and/or draining the separation according to methodologies of the present invention. Separation closure, irrigation and drainage methodologies are disclosed utilizing various combinations of closure screens, tubing, sutures, fluid transfer elements and gradient force sources. The use of mechanical forces associated with barbed strands for repositionably securing separated tissues together is disclosed. The use of same for eliminating or reducing the formation of subcutaneous voids or pockets, which can potentially form hematoma and seroma effects, is also disclosed. Further disclosed are alternative embodiment medical closure screen installation systems and methods.

A flexible medical closure screen for closing a separation of first and second tissue portions is provided, which includes a mesh screen comprising tubular vertical risers, vertical strands with barbed filaments, and horizontal spacers connecting the risers and strands in a grid-like configuration. An optional perimeter member partly surrounds the screen and can comprise a perimeter tube fluidically coupled with the vertical risers to form a tubing assembly. Various input/output devices can optionally be connected to the perimeter tube ends for irrigating and/or draining the separation according to methodologies of the present invention. Separation closure, irrigation and drainage methodologies are disclosed utilizing various combinations of closure screens, tubing, sutures, fluid transfer elements and gradient force sources. The use of mechanical forces associated with barbed strands for repositionably securing separated tissues together is disclosed. The use of same for eliminating or reducing the formation of subcutaneous voids or pockets, which can potentially form hematoma and seroma effects, is also disclosed. Alternative embodiment flexible closure screens and methods of using same are also disclosed.

A surgical drain device includes a matrix of biodegradable polymer material and a plurality of drain tubes attached to the matrix. The device is implanted within a surgical wound to treat the presence of seromas, for example, and is used to promote drainage, tissue adhesion, and wound closure. The drain tubes converge into a common collection tube that leads wound fluid outside the body under gravity feed or negative pressure applied to the collection tube. The matrix contains an array of apertures that allow tissue contact across the device. A preferred embodiment comprises a tissue anchoring system including anchor elements such as hooks or barbs. The device can be used with a negative pressure system to further improve the drainage band can also be used with a wound dressing. The device and systems containing the device are particularly useful to promote the healing of surgical wounds from abdominal surgery.

Adipose tissue-derived stromal cells induced to form multicellular aggregates can be formed reliably and consistently, they can be maintained for prolonged periods in adherent or suspension culture, and they are able to survive, grow, and/or differentiate in serum-free media conditions. The present invention provides compositions and methods for the use of such aggregates in tissue repair. This culture platform provides a controlled and defined system in which to study and standardize adult stem cell biology, and begets an instinctive “modular” approach to the predictable replacement and regeneration of adipose tissue.

The invention provides a method for producing a retinal tissue by (1) subjecting pluripotent stem cells to floating culture in a serum-free medium containing a substance inhibiting the Wnt signal pathway to form an aggregate of pluripotent stem cells, (2) subjecting the aggregate to floating culture in a serum-free medium containing a basement membrane preparation, and then (3) subjecting the aggregate to floating culture in a serum-containing medium. The invention also provides a method for producing an optic-cup-like structure, a method for producing a retinal pigment epithelium, and a method for producing a retinal layer-specific neural cell.

The invention is a postoperative binder and method of use. The binder is made of relatively inelastic material that is cut to fit the patient and held in place by a plurality of tails fastened with Velcro(R) binders. The present invention uses mechanical, rather than elastic, compression. Mechanical loads are carried over the iliac crest, by hooking the tails of the binder over the iliac crest and then bifurcating the tails for attachment to the abdominal portion of the binder. The present invention provides support of lower abdominal tissue, especially near the genitals and in the area of the peritoneum. The invention is also a method of preventing post-operative wound infection, reducing incidence of seroma and hematoma formation and wound separation while reducing pain and the need for pain medication by passing a relatively inelastic abdominal binder over the patient's iliac crest and abdomen to place the binder in tension so as to provide a greater than 180 degree radius of compression to the wound.

The invention discloses a specific culture medium for a lung tumor organ and a stentless 3D culturing method. The specific culture medium is prepared from the following components: FBS, double antibody, N-2, Noggin, B-27, EGF, FGF-10, Y-27632, A 83-01, SB202190, N-acetylcysteine, HEPES, Glutamax, IGF-1, hydrocortisone and Advanced DMEM/F12. The culturing method comprises the following steps: adding a tumor cell into a low serum culture medium, re-suspending the tumor cell, inoculating the tumor cell into a culture vessel, adding the specific culture medium into the culture vessel, changing thespecific culture medium once a day, and performing culturing until an organoid is formed. According to the culture medium and culturing method, a tumor organoid can quickly generate, can be stably cultured for a long time, is regular in spheroid form and has uniform and controllable size, and the heterogeneity of a tumor tissue of a patient can be well maintained in vitro.

The invention relates to a method for culturing an autologous peripheral blood lymphocyte. The method comprises the following steps: (1) separating a mononuclear cell from peripheral blood, resuspending in an X-VIVO15 serum-free culture medium to obtain cell concentration of 1*10<6>/mL, and culturing for 3 days; (2) supplementing the X-VIVO15 serum-free culture medium to 100 mL, adding IL-21*10<3> U/mL, and culturing for 1 day; (3) supplementing the X-VIVO15 serum-free culture medium to 200-240 mL, adding IL-21*10<3> U/mL, and culturing for 3 days; (4) supplementing the X-VIVO15 serum-free culture medium to 1000 mL, adding IL-21*10<3> U/mL, CTLA-4mAb100n g/mL and PD-1mAb100n g/mL; and (5) culturing for 5-7 days to prepare the autologous peripheral blood lymphocyte. The method disclosed by the invention can be used for improving the activation efficiency and amplification efficiency of an effector cell group by adding multiple monoclonal antibodies and cell factors to the X-VIVO15 serum-free culture medium, and can be used for effectively reducing the content of T regulatory cells by covering CTLA-4 and PD-1 molecules of the surfaces of all CIK cells by loading CTLA-4 and PD-1 antibodies in vitro especially, thus further enhancing the killing effect of the CIK cells on tumors.

The invention discloses an establishment method of a solitary pulmonary nodule malignancy probability prediction model. The establishment method particularly includes the steps: acquiring basic information of patients and serum tumor marker levels 1-7 days before operation; dividing patient cases into one group with GGO (ground glass opacity) lesion proportion higher than or equal to 50% and another group with GGO lesion proportion lower than 50% according to the GGO lesion proportion and CT (computed tomography) imaging reports of the patients; setting experiment groups and validation groups in each group of cases according to the proportion of 3:1, performing single-factor analysis on relative data of cases of the experiment groups to initially screen independent risk factors; substituting the independent risk factors into multifactor analysis to obtain independent risk factors for judging benign and malignant SPNs (solitary pulmonary nodules); acquiring the SPN malignancy probability prediction model by the aid of Logistic regression; substituting case data of the validation groups into the model, and verifying the case data of the validation groups. The model is simple and easy to use, used indexes can be acquired by the aid of routine examination and are easy to use, and effective intermediate reference information can be provided for further diagnosis and treatment of doctors according to the model.

A whole blood hollow fiber membrane filter medium is made of a polymeric material having pores of a pore size that ensures permeability to blood plasma or serum but retains blood cells. The whole blood hollow fiber membrane filter medium is used for filtering a whole blood sample so that blood plasma or serum passes through the whole blood hollow fiber membrane filter medium and blood cells are retained. The obtained blood plasma shows no hemolysis.

The invention provides a method for separating and culturing umbilical cord blood mesenchymal stem cells. The method comprises the steps of carrying out secondary separation on umbilical cord blood mononuclear cells by using a separating medium, and then inoculating the umbilical cord blood mononuclear cells into a culture bottle in which fibronectin and CD90 monoclonal antibodies are coated; and culturing for 4-5 days by using a serum-free culture system and simulating the in-vivo low-oxygen growth environment of the mesenchymal stem cells, then, removing suspension cells, further culturing adherent cells, and subculturing after the fusion rate of primary cells is up to 60%. By using the method for separating and culturing umbilical cord blood mesenchymal stem cells, provided by the invention, the problems of adherence infirmness, low culture success rate, low purity and the like caused in the extraction and culture processes of the umbilical cord blood mesenchymal stem cells are effectively solved, and the safety in clinical application is improved. In addition, the application ranges of the umbilical cord blood mesenchymal stem cells are widened, the utilization values of the umbilical cord blood mesenchymal stem cells are developed, and the clinical application prospects of the umbilical cord blood mesenchymal stem cells are widened.

The invention relates to a method of inducing and differentiating human umbilical cord derived mesenchymal stem cells into cartilage cells. The method includes: in order to solve the problem that the prior art is low in differentiation efficiency, cleaning umbilical cord tissue to remove blood stain, cutting the same into small sections, dissecting the small sections to remove vascular tissue, cutting the small sections into pieces, and digesting to obtain a single mesenchymal stem cell; culturing the obtained mesenchymal stem cell in an amplification manner to the seventh generation to obtain a unicellular suspension, inoculating the unicellular suspension into a serum-free culture medium containing a cartilage differentiation inducer to continue culturing, replacing a fresh culture medium every other 3.5 days, and inducing for 14 days to obtain the cartilage cells. The method can efficiently differentiate the umbilical cord mesenchymal stem cells into the cartilage cells and is of important significance in the aspects of restoring cartilage tissue in human bodies and treating bone injury.

The invention relates to a method for culturing autologous peripheral blood lymphocytes, comprising the following steps of: (1) separating a PBMC (Peripheral Blood Mononuclear Cell) from peripheral blood, then heavily suspending in a serum-free culture medium, and statically culturing to prepare a primary culture solution; (2) replenishing the serum-free culture medium to the primary culture solution, simultaneously adding IL (Interleukin)-2, and statically culturing to prepare a secondary culture solution; (3) replenishing the serum-free culture medium to the secondary culture solution, simultaneously adding IL-2, and statically culturing to prepare a culture solution; and (4) uniformly dividing the culture solution into two parts, adding the serum-free culture medium to complement a sufficient volume, adding IL-2, statically culturing, and repeating the step (4) to prepare the autologous peripheral blood lymphocytes. As multiple monoclonal antibodies and cell factors are added to the serum-free culture medium, the activation efficiency and the amplification efficiency of effector cell masses are improved. Through detection, the activation efficiency and the amplification efficiency are obviously improved as compared with the existing method, and a large amount of cell masses occur after the effector cell masses are activated about 3 days.

The invention discloses freezing storage protective solution for a human umbilical Wharton's jelly tissue block. 1 liter of the freezing storage protective solution comprises 0.8 to 1.2 mol of glycol, 0.4 to 0.6 mol of dimethyl sulfoxide, 0.1 to 0.3 mol of cane sugar, 100 to 200 milliliters of cord blood autoserum and the balance of culture solution DMEM/F12. In the freezing storage protective solution, the cord blood autoserum and the culture solution DMEM/F12 serve as base solution to provide nutrient for the tissue block, so osmotic equilibrium inside and outside cells is guaranteed, the cell environment in the tissue block is guaranteed to be similar to the in vivo environment, and the freezing storage effect is good; the low-concentration glycol and dimethyl sulfoxide serve as a permeability freezing protective agent, so the toxicity of the freezing storage protective solution to the cells is reduced; and the cane sugar serves as a non-permeability freezing protective agent, so the viscosity of the solution is increased and the osmotic pressure inside and outside cell membranes is relieved when the cells are frozen and stored. The human umbilical Wharton's jelly tissue block can be directly frozen and stored by the freezing storage protective solution, so the freezing storage effect is good, the cell damage is little, and high-quality human umbilical mesenchymal stem cells can be provided for clinic.

A system and apparatus for the collection of serous or serosanguinous fluid from a percutaneous site after surgery. A pump unit with one or more pumps or powered sources provide continuous negative pressure suction to draw fluid from the percutaneous site and pumps the fluid into disposable reservoirs with one-way valves that are easy to handle while maintaining sterility and a seal to prevent the loss of vacuum. Air is continuously removed from the reservoirs. Measurement and analysis of the output is performed automatically.

A method for forming neuromuscular junctions includes forming functional neuromuscular junctions between motoneurons and muscle cells by co-culturing one or more human motoneurons and one or more rat muscle cells in a substantially serum-free medium. A synthetic mammalian neuromuscular junction includes a human motoneuron functionally linked to a rat muscle cell in a substantially serum-free medium. An artificial substrate may be used to support the one or more neuromuscular junctions.

The invention relates to preservation of human local living parts and in particular relates to a culture medium for keeping primary airway epithelial cells in the physiological state in vivo during in vitro culture. The invention is characterized in that the culture medium contains the following components (per liter), 12 g of DMEM/F12 medium, 30 mg of penicillin G sodium salt, 50 mg of streptomycin, 10 mg of insulin, 5 mg of transferring, 25 Mug of epidermal growth factors, 100 Mug of cholera toxin, 108.741 Mug of hydrocortisone, 1 g of bovine pituitary extract, 3 g of bovine serum albumin, 1.5*10<-2> Mug of retinoic acid, 50 mg of gentamycin, 0.5 mg of amphotericin B, 50 mL of fetal calf serum and the balance of water. The primary airway epithelial cells cultured by the culture medium have the ciliary beating function and can maintain the physiological state in vivo.